STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.

Gonçalves LCP, Rastoin O, Morozova V, Buzet C, Bennetot A, Pagès G, Ronco C, Dufies M.

Open source

DOI
10.7150/thno.129910
Published
2026-03-30
Container
Theranostics
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.7150/thno.129910,
  title = {STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.},
  author = {Gonçalves LCP and  Rastoin O and  Morozova V and  Buzet C and  Bennetot A and  Pagès G and  Ronco C and  Dufies M.},
  year = {2026},
  journal = {Theranostics},
  doi = {10.7150/thno.129910},
  url = {https://doi.org/10.7150/thno.129910}
}

RIS

TY  - JOUR
TI  - STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.
AU  - Gonçalves LCP
AU  -  Rastoin O
AU  -  Morozova V
AU  -  Buzet C
AU  -  Bennetot A
AU  -  Pagès G
AU  -  Ronco C
AU  -  Dufies M.
PY  - 2026
JO  - Theranostics
DO  - 10.7150/thno.129910
UR  - https://doi.org/10.7150/thno.129910
ER  - 

APA

LCP, G., O, R., V, M., C, B., A, B., G, P., C, R., & M., D. (2026). STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.. Theranostics. https://doi.org/10.7150/thno.129910

Source records